Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A
Main Authors: | Shahram Attarian, Peter Young, Thomas H. Brannagan, David Adams, Philip Van Damme, Florian P. Thomas, Carlos Casanovas, Jafar Kafaie, Céline Tard, Maggie C. Walter, Yann Péréon, David Walk, Amro Stino, Marianne de Visser, Camiel Verhamme, Anthony Amato, Gregory Carter, Laurent Magy, Jeffrey M. Statland, Kevin Felice |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-04-01
|
Series: | Orphanet Journal of Rare Diseases |
Online Access: | https://doi.org/10.1186/s13023-024-03110-3 |
Similar Items
-
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A
by: Shahram Attarian, et al.
Published: (2021-10-01) -
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
by: Thomas Prukop, et al.
Published: (2019-01-01) -
Drosophila eggshell production: identification of new genes and coordination by Pxt.
by: Tina L Tootle, et al.
Published: (2011-01-01) -
Structural basis for proapoptotic activation of Bak by the noncanonical BH3-only protein Pxt1.
by: Dahwan Lim, et al.
Published: (2023-06-01) -
Allelic variations between vaccine strains and circulating strains in pxtP of Bordetella pertussis in Iran
by: F Sadeghpour Heravi, et al.
Published: (2015-05-01)